Indaptus Therapeutics is trading 6.63% higher at $4.02, with no company-specific announcement or regulatory catalyst identified for September 24, 2026.
- The approximately $24 million private placement involved 20,338,974 shares and was reported earlier in September.
- The stock has had a volatile week, and the gain does not clearly align with broader biotech performance.